Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Regen Biopharma ( (RGBP) ) just unveiled an update.
On October 2, 2025, Regen Biopharma, Inc. entered into consulting agreements with Dr. Harry Lander and CEO David Koos, granting each twenty million newly issued common shares subject to vesting, to support a planned Phase I clinical trial of HemaXellerate. This trial aims to assess the safety and efficacy of the therapy in patients with severe aplastic anemia, potentially impacting the company’s market position and stakeholder interests.
More about Regen Biopharma
Regen Biopharma, Inc. operates in the biotechnology industry, focusing on developing stem cell therapies. Its primary product, HemaXellerate, is a cellular composition derived from adipose tissue, aimed at treating drug-refractory aplastic anemia.
Average Trading Volume: 297,579
Technical Sentiment Signal: Strong Sell
Current Market Cap: $427.8K
See more data about RGBP stock on TipRanks’ Stock Analysis page.